Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2002 1
2004 1
2017 1
2018 1
2019 3
2020 1
2021 4
2022 3
2023 2
2024 3
2025 4
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Migraine in women: a review.
Ghadiri-Sani M. Ghadiri-Sani M. Curr Opin Neurol. 2025 Jun 1;38(3):271-276. doi: 10.1097/WCO.0000000000001372. Epub 2025 Apr 23. Curr Opin Neurol. 2025. PMID: 40265504 Review.
Consequently, women use more acute and preventive medications, have more comorbid conditions and are more likely to run a chronic disease course.Real-life experience and evidence suggest that onabotulinumtoxinA and the newer generation antibody treatments against the calci …
Consequently, women use more acute and preventive medications, have more comorbid conditions and are more likely to run a chronic disease co …
Migraine treatment: Position paper of the French Headache Society.
Moisset X, Demarquay G, de Gaalon S, Roos C, Donnet A, Giraud P, Guégan-Massardier E, Lucas C, Mawet J, Valade D, Corand V, Gollion C, Moreau N, Grangeon L, Lantéri-Minet M, Ducros A. Moisset X, et al. Rev Neurol (Paris). 2024 Dec;180(10):1087-1099. doi: 10.1016/j.neurol.2024.09.008. Epub 2024 Oct 15. Rev Neurol (Paris). 2024. PMID: 39406556 Free article. Review.
The first important message concerns the position of the French Headache Society on the use of preventive treatments (monoclonal antibodies and gepants) targeting the calcitonin gene-related peptide (CGRP) pathway. ...As a result, this treatment is formally c …
The first important message concerns the position of the French Headache Society on the use of preventive treatments (monoclonal a …
The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine.
Cohen F, Yuan H, DePoy EMG, Silberstein SD. Cohen F, et al. Neurotherapeutics. 2022 Apr;19(3):922-930. doi: 10.1007/s13311-022-01230-x. Epub 2022 Apr 14. Neurotherapeutics. 2022. PMID: 35426060 Free PMC article. Review.
Understanding the molecular mechanism of calcitonin gene-related peptide (CGRP) has led to the discovery of a novel class of drugs, CGRP functional blocking monoclonal antibodies (mAbs), for migraine prevention. ...MAbs display minimal drug interaction …
Understanding the molecular mechanism of calcitonin gene-related peptide (CGRP) has led to the discovery of a novel class of drugs, …
Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: Updated analysis in VigiBase .
Noseda R, Bedussi F, Gobbi C, Ceschi A, Zecca C. Noseda R, et al. Cephalalgia. 2023 Apr;43(4):3331024231158083. doi: 10.1177/03331024231158083. Cephalalgia. 2023. PMID: 36855950 Free article.
BACKGROUND: Safety data on the use of migraine preventive monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) system in pregnancy are limited. ...As primary outcome, the whole group of monoclonal antibodies targetin …
BACKGROUND: Safety data on the use of migraine preventive monoclonal antibodies targeting the calcitonin gene-related peptide …
Case series on monoclonal antibodies targeting calcitonin gene-related peptide in migraine patients during pregnancy: Enhancing safety data.
Elosua-Bayes I, Alpuente A, Melgarejo L, Caronna E, Torres-Ferrús M, Pozo-Rosich P. Elosua-Bayes I, et al. Cephalalgia. 2024 Sep;44(9):3331024241273966. doi: 10.1177/03331024241273966. Cephalalgia. 2024. PMID: 39314064 Free article. Review.
BACKGROUND: Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP-mAbs) are approved for adult migraine prevention but pose safety concerns in pregnancy. ...METHODS: Six migraine-diagnosed women received CGRP-mAbs; treatment ceas …
BACKGROUND: Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP-mAbs) are approved for adult migraine …
Calcitonin gene-related peptide (CGRP) monoclonal antibodies for migraine.
Giffin NJ. Giffin NJ. Pract Neurol. 2023 Jun;23(3):200-207. doi: 10.1136/pn-2022-003592. Epub 2023 Feb 8. Pract Neurol. 2023. PMID: 36754606 Review.
The introduction of calcitonin gene-related peptide monoclonal antibodies represents a step forward in preventive migraine treatment as the first agents to target the underlying pathogenesis of migraine. ...Major disadvantages are their high cost and unknown safety …
The introduction of calcitonin gene-related peptide monoclonal antibodies represents a step forward in preventive migraine tre …
A Monoclonal Anti-Calcitonin Gene-Related Peptide Antibody Decreases Stress-Induced Colonic Hypersensitivity.
Noor-Mohammadi E, Ligon CO, Mackenzie K, Stratton J, Shnider S, Greenwood-Van Meerveld B. Noor-Mohammadi E, et al. J Pharmacol Exp Ther. 2021 Nov;379(3):270-279. doi: 10.1124/jpet.121.000731. Epub 2021 Oct 7. J Pharmacol Exp Ther. 2021. PMID: 34620725 Free article.
Here, we used a monoclonal anti-CGRP divalent antigen-binding fragment [F(ab')(2)] antibody to test the hypothesis that inhibition of peripheral CGRP signaling reverses colonic hypersensitivity induced by either chronic adult stress or early life stres …
Here, we used a monoclonal anti-CGRP divalent antigen-binding fragment [F(ab')(2)] antibody to test the hypothesis that …
CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications.
Dodick DW. Dodick DW. Cephalalgia. 2019 Mar;39(3):445-458. doi: 10.1177/0333102418821662. Epub 2019 Jan 19. Cephalalgia. 2019. PMID: 30661365 Review.
BACKGROUND: Monoclonal antibodies that target calcitonin gene-related peptide or the canonical calcitonin gene-related peptide receptor have emerged as effective and well tolerated for the preventive treatment of migraine. ...CONCLUSIONS: Calcitonin gene-related pep …
BACKGROUND: Monoclonal antibodies that target calcitonin gene-related peptide or the canonical calcitonin gene-related peptide …
Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine.
Wells-Gatnik WD, Pellesi L, Martelletti P. Wells-Gatnik WD, et al. Expert Rev Neurother. 2024 Nov;24(11):1107-1117. doi: 10.1080/14737175.2024.2401558. Epub 2024 Sep 12. Expert Rev Neurother. 2024. PMID: 39264231 Review.
Current areas of potential therapeutic innovation for rimegepant and atogepant include the pediatric population, in pregnancy and breastfeeding, in cluster headache and post-traumatic headache, and in patients that previously discontinued calcitonin gene-related peptide ( …
Current areas of potential therapeutic innovation for rimegepant and atogepant include the pediatric population, in pregnancy and bre …
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
Simioni CVMG. Simioni CVMG. Arq Neuropsiquiatr. 2022 May;80(5 Suppl 1):214-217. doi: 10.1590/0004-282X-ANP-2022-S125. Arq Neuropsiquiatr. 2022. PMID: 35976315 Free PMC article.
There have been unforeseen problems with the use of preventive treatment of migraine with oral drugs, mainly due to side-effects that cannot be tolerated and lack of efficacy, leading to high discontinuation rates. Anti-CGRP monoclonal antibodies (mAbs) have …
There have been unforeseen problems with the use of preventive treatment of migraine with oral drugs, mainly due to side-effects that cannot …
28 results